At a glance
- Originator Torii Pharmaceutical
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Nephritis
Most Recent Events
- 31 Oct 2006 Discontinued for Autoimmune disorders in Japan (PO)
- 31 Oct 2006 Discontinued for Nephritis in Japan (PO)
- 22 May 2001 No-Development-Reported for Autoimmune disorders in Japan (PO)